All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Quizartinib granted approval in Japan for the treatment of patients with newly diagnosed AML with FLT3-ITD mutations

May 26, 2023
Learning objective: After reading this article, learners will be able to cite a new development in the treatment of newly diagnosed AML.

Bookmark this article

On May 25, 2023, quizartinib, an oral, highly potent and selective type II FLT3 inhibitor was approved by Japan’s Ministry of Health, Labour, and Welfare (MHLW) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with FLT3-internal tandem duplication (FLT3-ITD) mutations.1

This approval is for use in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as maintenance monotherapy. Quizartinib is the first FLT3 inhibitor approved for newly diagnosed patients with AML in Japan, having received approval in 2019 as a monotherapy in the relapsed/refractory AML setting.1

This approval is based on the results from the randomized, double-blind, placebo-controlled, phase III QuANTUM-First trial (NCT02668653), which has been previously covered on the AML Hub. In this trial, the addition of quizartinib to standard cytarabine and anthracycline induction and standard cytarabine consolidation, and quizartinib maintenance monotherapy was associated with a 22.4% reduction in the risk of death when compared with standard chemotherapy alone (hazard ratio, 0.78; 95% confidence interval [CI], 0.62–0.98; p = 0.032).1 Median overall survival in the quizartinib arm (n = 268) was 31.9 months (95% CI, 21.0–NE) compared with 15.1 months (95% CI, 13.2–26.2) in the standard chemotherapy arm (n = 271).1 The most common adverse reactions in patients who received quizartinib were neutropenia (25.0%), thrombocytopenia (22.7%), nausea (20.6%), and electrocardiogram QT prolonged (19.3%), consistent with previous reports.1

  1. Daiichi Sankyo. VANFLYTA® first FLT3 inhibitor approved in Japan for patients with newly diagnosed FLT3-ITD positive AML. Published May 25, 2023. Accessed May 26, 2023.


Subscribe to get the best content related to AML delivered to your inbox